At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 58 enrolled
Drug / intervention
AZD9150drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I/Ib, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of AZD9150 in Patients With Advanced/Metastatic Hepatocellular Carcinoma
In Brief
A Phase 1 clinical trial evaluating AZD9150 for Advanced Adult Hepatocellular Carcinoma and Hepatocellular Carcinoma Metastatic. Completed, enrolled 58 participants across 7 sites in 4 countries.
Detailed Summary
This is a phase I/Ib open-label, multicentre study to assess the safety, tolerability, pharmacokinetics and preliminary anti-tumour activity of AZD9150 in patients with advanced/metastatic hepatocellular carcinoma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesHong Kong, Japan, South Korea, Taiwan
CollaboratorsIonis Pharmaceuticals, Inc.
Timeline
Phase 1CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedApr 2013
Enrollment StartMay 2013
Primary CompletionFeb 2015
TodayJul 2026
First PostedApr 25, 2013
Enrollment StartMay 1, 2013
Primary CompletionFeb 1, 2015
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 13.2 years ago
Interventions
AZD9150drug
Intravenous infusion over 3 hours.